CV-2-CoV

N/A

Report date: 2026/05/12 09:10:27

Base Information

Drug NameCV-2-CoV
Drug Alias NameCV-2-CoV
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccineCell and gene therapy > Gene therapy > mRNAVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulantsCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCurevac AgGlaxosmithkline Spa
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcCurevac AgGlaxosmithkline Spa
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A